Tenaya Therapeutics
Presença
Tenaya Therapeutics é uma das ...
Tenaya Therapeutics é uma empresa listada sob o símbolo TNYA (US).
Executivos
Veja o organograma con seus 30 executivos principais
Biografias mais buscadas da Tenaya Therapeutics
Criar um alerta
para seguir os movimentos de executivos da Tenaya Therapeutics.
Biotecnologia
Tenaya Therapeutics possui 2.290 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Delphia Therapeutics acaba de anunciar uma arrecadação de fundos de 67 milhões de dólares. (publicado em 7 de maio de 2024).
- Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Tenaya Therapeutics
- Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference | Tenaya Therapeutics, Inc.
- Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Tenaya Therapeutics
- Tenaya Therapeutics na Wikipedia, Google News e Yahoo Finance
- Tenaya Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Faraz Ali 
Ligue para a Tenaya Therapeutics em +1 760...
